What is the ideal combination therapy in de novo, oligometastatic, castration-sensitive prostate cancer?

Michael BaboudjianGuilhem RoubaudGaëlle FromontMathieu GauthéJean-Baptiste BeauvalEric BarretLaurent BrureauGilles CréhangeCharles DarianeGaëlle FiardRomain MathieuAlain RuffionMorgan RouprêtRaphaële Renard-PennaPaul SargosGuillaume Ploussardnull null

Published in: World journal of urology (2022)

The present review discusses current data in de novo, omPCa regarding its definition, the increasing role of molecular imaging, the place of local and metastasis-directed therapies, and the intensification of systemic therapies.

Keyphrases

combination therapy
prostate cancer
radical prostatectomy
electronic health record
big data
machine learning